Christian Joseph Ong

Dr. Christian Joseph Ong

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2024 in European Journal of Microbiology and Immunology
Verified
Journal Article
Open access
PDF file
JFJamil Allen Gamboa Fortaleza
Jamil Allen Gamboa Fortaleza
COChristian Joseph Ong
Christian Joseph Ong
RJRener De Jesus
Rener De Jesus
Staphylococcus aureus infections have already presented a substantial public health challenge, encompassing different clinical manifestations, ranging from bacteremia to sepsis and multi-organ failures. Among these infections, methicillin-resistant S. aureus (MRSA) is particularly alarming due to its well-documented resistance to multiple classes of antibiotics, contributing significantly to global mortality rates. Consequently, the urgent need for effective treatment options has prompted a growing interest in exploring phage therapy as a potential non-antibiotic treatment against MRSA infections. Phages represent a class of highly specific bacterial viruses known for their ability to infect certain bacterial strains. This review paper explores the clinical potential of phages as a treatment for MRSA infections due to their low toxicity and auto-dosing capabilities. The paper also discusses the synergistic effect of phage-antibiotic combination (PAC) and the promising results from in vitro and animal model studies, which could lead to extensive human clinical trials. However, clinicians need to establish and adhere to standard protocols governing phage administration and implementation. Prominent clinical trials are needed to develop and advance phage therapy as a non-antibiotic therapy intervention, meeting regulatory guidelines, logistical requirements, and ethical considerations, potentially revolutionizing the treatment of MRSA infections.

16 December 2025 in European Journal of Microbiology and Immunology
Verified
Journal Article
Open access
COChristian Joseph Ong
Christian Joseph Ong
OEOluwagbemisola Elizabeth Elesho
Oluwagbemisola Elizabeth Elesho
BBBolorunduro Babatunde Bramwell
Bolorunduro Babatunde Bramwell
KCKevin Smith Puno Cabuhat
Kevin Smith Puno Cabuhat
GBGrace D. Bacalzo
Grace D. Bacalzo
JFJamil Allen Gamboa Fortaleza
Jamil Allen Gamboa Fortaleza
Staphylococcus aureus is a clinically important bacterial pathogen causing infections from superficial skin lesions to life-threatening systemic diseases. The emergence of methicillin-resistant S. aureus (MRSA) has compounded the global health burden, particularly in low- and middle-income countries, as its quorum-sensing (QS) mediated mechanisms contribute to its persistence, resistance, and evasion from host immune responses and antimicrobial treatments. Thus, these features compromise the effectiveness of conventional antibiotics, urging the need for alternative therapeutic approaches. To resolve these issues, several non-antibiotic antibiofilm approaches have been developed. Bacteriophages and phage-derived enzymes show promising specificity in lysing bacterial cells and disrupting biofilms. Antimicrobial peptides (AMPs), with their broad-spectrum activity, destabilize bacterial membranes and modulate immune responses. Monoclonal antibodies can neutralize toxins or inhibit adhesion molecules within biofilms. Phytochemicals have demonstrated activity against QS pathways and efflux pumps. Metal ion chelators like deferiprone interfere with iron acquisition, which is essential for biofilm stability. Nanoparticles (NPs), ranging from metallic and polymeric to lipid-based and cyclodextrin-based systems, enhance drug delivery and biofilm penetration. CRISPR-Cas systems provide precise genome editing to target resistance genes and virulence factors. Rhamnolipids disrupt biofilm matrix integrity, while enzymes such as dispersin B degrade extracellular polymeric substances. Photodynamic and laser therapies offer localized disruption of biofilm structures through oxidative stress. Collectively, this review offers a transformative complementary approach to traditional antibiotics, enhancing treatment efficacy while potentially reducing the emergence of resistance. Continued research on delivery systems, safety profiles, and synergistic combinations will be pivotal for their clinical translation against S. aureus infections.

31 December 2025 in European Journal of Microbiology and Immunology
Verified
Journal Article
Open access
KCKevin Smith Puno Cabuhat
Kevin Smith Puno Cabuhat
TTTroy Vincent C. Tan
Troy Vincent C. Tan
COChristian Joseph Ong
Christian Joseph Ong
Ferdinand Apolonio MortelFerdinand Apolonio Mortel
Ferdinand Apolonio Mortel
GBGrace D. Bacalzo
Grace D. Bacalzo
JFJamil Allen Gamboa Fortaleza
Jamil Allen Gamboa Fortaleza
Antimicrobial resistance (AMR), particularly in methicillin-resistant Staphylococcus aureus (MRSA), continues to threaten global health due to its multidrug resistance and strong biofilm-forming ability. Antimicrobial peptides (AMPs) have emerged as promising agents against MRSA biofilms because of their diverse origins, structural versatility, and unique modes of action. Natural AMPs derived from animals, plants, fungi, protists, archaea, and bacteria primarily act by disrupting bacterial membranes, interfering with quorum sensing, and downregulating biofilm-related genes such as sarA , icaA , and icaD . Synthetic AMPs, designed through computational modeling and machine learning, demonstrate enhanced stability, reduced toxicity, and improved target specificity. Synergistic AMP–antibiotic combinations, including nisin, indolicidin, and α-MSH analogs with β-lactams, significantly improve antibiofilm efficacy and bacterial clearance. Despite these advances, challenges persist due to peptide instability, enzymatic degradation, cytotoxicity, and limited in vivo validation. Recent developments in nanoparticle, hydrogel, coatings, and nanofiber delivery systems have improved AMP bioavailability and controlled release within biofilms. Continued integration of peptide engineering, nanotechnology, and bioinformatics-driven design offers promising solutions for clinical translation. Overall, AMPs represent a frontier in combating MRSA biofilms and antibiotic resistance, with future research focusing on stability enhancement, resistance prevention, and optimized therapeutic delivery.

4 May 2026 in Virulence
Verified
Journal Article
Open access
JFJamil Allen Gamboa Fortaleza
Jamil Allen Gamboa Fortaleza
KCKevin Smith Puno Cabuhat
Kevin Smith Puno Cabuhat
COChristian Joseph Ong
Christian Joseph Ong
Ferdinand Apolonio MortelFerdinand Apolonio Mortel
Ferdinand Apolonio Mortel
GBGrace D. Bacalzo
Grace D. Bacalzo
JNJose Jurel M. Nuevo
Jose Jurel M. Nuevo
Acinetobacter baumannii, once regarded as a low-virulence organism, has emerged as a major global pathogen due to the rapid dissemination of multidrug-resistant (MDR), extensively drug-resistant (X...

23 October 2023 in Journal of Pure and Applied Microbiology
Verified
Journal Article
Open access
NSNoelle Christelledes Santos
Noelle Christelledes Santos
MCMa. Eloisa Butiong Cabrera
Ma. Eloisa Butiong Cabrera
JFJanry Durano Flores
Janry Durano Flores
RJRaymundo Fajardo Javier
Raymundo Fajardo Javier
OAOliver Redondo Alaijos
Oliver Redondo Alaijos
COChristian Joseph Ong
Christian Joseph Ong

30 May 2026 in Tropical Medicine and Health
Verified
Journal Article
Open access
PDF file
RNRahmatullah Nazari
Rahmatullah Nazari
SQShabrina Arifia Qatrannada
Shabrina Arifia Qatrannada
MJMurtaza Jafari
Murtaza Jafari
SASayed Hussain Amiri
Sayed Hussain Amiri
COChristian Joseph Ong
Christian Joseph Ong
DIDon Eliseo Lucero-Prisno III
Don Eliseo Lucero-Prisno III
Introduction: Antimicrobial resistance (AMR) is a critical and escalating public health threat globally, with Southeast Asia facing particularly high burdens due to elevated antimicrobial consumption, fragmented health systems, and uneven regulatory enforcement. Although member states of the Association of Southeast Asian Nations (ASEAN) have introduced AMR-related initiatives aligned with the Global Action Plan on AMR, the regional evidence base remains dispersed, fragmented across sectors, and insufficiently synthesized from a One Health perspective. This scoping review aimed to systematically map implemented AMR interventions across ASEAN countries, characterize their implementation patterns, assess the extent of One Health integration, and identify evidence gaps. Methods: We conducted a scoping review following PRISMA-ScR guidelines. PubMed/MEDLINE, Scopus, and ScienceDirect were searched for empirical studies published between January 1, 2018, and December 31, 2025, that reported the implementation of AMR-related programs, policies, or interventions in ASEAN member states. Data on country, sector, setting, intervention type, One Health pillar, study design, and outcomes were extracted and analyzed using narrative synthesis. Results: Of 9,832 records screened, 57 studies met the inclusion criteria. Evidence was heavily concentrated in three countries: Thailand (n = 15, 26.3%), Singapore (n = 13, 22.8%), and Vietnam (n = 12, 21.1%), accounting for 70.2% of all studies. Critically, no eligible peer-reviewed studies were identified from Brunei Darussalam, while Laos and Cambodia were represented only through disaggregated data from one multi-country surveillance study. The human health sector dominated (86.0%), while only 8.8% of studies adopted integrated One Health approaches, and no studies addressed the environmental sector in isolation. Antimicrobial stewardship was the most common intervention (63.2% of studies), but explicit use of implementation science frameworks was rare. Fifteen studies (26.3%) evaluated multi-component interventions, indicating an emerging shift toward integrated strategies. Most studies employed observational designs (50.9%) and assessed short-term process outcomes rather than sustained resistance reduction. Conclusions: This comprehensive mapping of AMR interventions across all ten ASEAN countries reveals extreme geographical and sectoral inequities. The complete absence of evidence from three member states and the dominance of hospital-based human health interventions underscore the urgent need for targeted investment in underrepresented settings and genuinely integrated One Health approaches. Without such advances, antimicrobial resistance initiatives in ASEAN will remain fragmented and unable to achieve sustained population-level impact.